PharmaFocus Today – media

Bivalirudin for injection obtains marketing authorization from the Australian Therapeutic Goods Administration

One May 6, Shuangcheng pharma announced that the company recently received the marketing authorization for bivalirudin for injection issued by the Australian Therapeutic Goods Administration. The drug is used to treat patients with medium- and high-risk acute coronary syndrome (ACS) and can be used in combination with aspirin. Previously, the company had obtained the “Drug Registration Approval” approved and issued by the National Drug Administration for the drug, and passed the National Drug Administration’s injection generic drug quality and efficacy consistency evaluation. The Australian marketing authorization will have a positive impact on the company’s expansion of overseas markets and improvement of the company’s performance. However, the export business of drugs is affected by many factors, and there is uncertainty in the sales time, market size and subsequent expansion progress. https://finance.eastmoney.com/a/202505063396845130.html
- Source: drugdu
- 31
- May 8, 2025
HDM2005 for injection obtains drug clinical trial approval notice

Huadong Medicine announced on the evening of May 6 that its wholly-owned subsidiary Zhongmei Huadong received the “Notice of Approval for Drug Clinical Trial” approved and issued by the National Medical Products Administration (NMPA). The clinical trial application for HDM2005 for injection submitted by Zhongmei Huadong was approved. This product is combined with rituximab, cyclophosphamide, doxorubicin (or epirubicin) and prednisone (R-CHP) to treat diffuse large B-cell lymphoma (DLBCL) that has not been previously treated with systemic treatment. https://finance.eastmoney.com/a/202505063396854169.html
- Source: drugdu
- 32
- May 8, 2025
The 10 billion-dollar ankylosing spondylitis market is undergoing a transformation

In January, Zhixiang Jintai’s Celicizumab Injection was approved for a new indication, becoming the first domestically produced IL-17A inhibitor approved for the AS indication in China; in March, Hengrui Medicine’s JAK1 inhibitor Amacitinib Tablets were approved for marketing, with ankylosing spondylitis as the first indication; then in April, another product of Hengrui Medicine – Fulanixzumab Injection became the second domestically produced IL-17A inhibitor approved for AS. The strong breakthrough of domestic innovative drugs represented by Hengrui Medicine has not only broken the long-term monopoly of similar imported drugs and provided Chinese AS patients with new treatment options, but also marked the transformation of domestic innovative drugs from “followers” to “game changers”, injecting new vitality into the tens of billions of AS drug treatment market. Billion-dollar drug treatment market Ankylosing spondylitis is a disease caused by autoimmune disorders that causes chronic inflammation of the joints of the body, mainly damaging the ...
- Source: drugdu
- 27
- May 8, 2025
The 100 billion yuan autoimmune disease prevention market, the next outbreak point

In the field of autoimmune therapy, traditional biologics have long dominated the market. Although classic drugs represented by Humira have significant therapeutic effects, they have limitations such as the need for frequent injections and potential risks of infection, which lead to low patient compliance. In sharp contrast, oral autoimmune drugs are rising rapidly and becoming the next explosion point in the industry due to their multiple advantages such as convenient home administration, no need for cold chain transportation, and controllable production costs. The next hot spot Globally, there are approximately 100 different types of autoimmune diseases, which can affect almost any part of the body, from the skin to the joints to the digestive system. Epidemiological data show that the patient population covered by major indications such as psoriasis, atopic dermatitis, and asthma has exceeded 100 million, constituting the core treatment needs in the autoimmune field. According to Frost & ...
- Source: drugdu
- 27
- May 8, 2025
Medical research has found that those who did not develop lung cancer despite having pneumonia all had these three dietary habits.

The lungs have just gone through a “storm”, and the worst thing is to leave behind hidden problems. Those who have recovered from pneumonia and have maintained a safe distance from lung cancer have secrets hidden in their plates. The latest medical observation has found that three “lung protectors” always appear on the diet lists of these people. I. The “Antioxidant Trio” Always Present on the Table 1. The protective shield of chlorophyll in dark-colored vegetables Consume at least 200 grams of dark green vegetables such as spinach and broccoli every day. These vegetables are rich in chlorophyll, which can neutralize free radicals produced by lung inflammation. The recommended cooking method is cold preparation to retain the maximum nutrients. 2. The natural anti-inflammatory agents in colorful fruits and vegetables The carotenoids in red and yellow fruits and vegetables, as confirmed by research, can reduce the risk of lung cancer. Eat ...
- Source: drugdu
- 26
- May 8, 2025
Exercising just one or two days a week can also lead to long-term health benefits.

The latest research by Chinese scientists shows that people can achieve the health benefits of daily exercise by engaging in physical activities for moderate to vigorous intensity for 1 to 2 days a week, as long as the total duration is at least 150 minutes per week. This research report was published in the recent issue of the “American Heart Association Journal”. Dr. Li Zhihao, an epidemiologist from Southern Medical University in Guangzhou, said that engaging in 150 minutes of moderate to vigorous physical activity per week, whether concentrated in 1 to 2 days or spread out over time, can significantly reduce the risk of death from cardiovascular diseases, cancer, or other causes. Those who cannot schedule physical exercise every day can focus on high-intensity activities on weekends. This study provides reliable evidence that even occasional physical activity can bring long-term health benefits, making it easier for people to prioritize ...
- Source: drugdu
- 25
- May 8, 2025
The Neuralink brain computer interface device has obtained FDA’s “Breakthrough Device” certification; Hengrui Pharmaceutical Passes Hong Kong Stock Exchange Listing Hearing | Pharmaceutical Early Participation

NO.1 Hengrui Pharmaceutical has passed the listing hearing on the Hong Kong Stock Exchange and may be listed as early as May On May 5th, the Hong Kong Stock Exchange website posted the PHIP version of Hengrui Pharmaceutical’s prospectus, which the market interpreted as indicating that Hengrui Pharmaceutical has officially passed the hearing of the Hong Kong Stock Exchange. Hengrui Pharmaceutical told the Daily Economic News reporter that this move marks a crucial progress for the company’s listing in Hong Kong. According to informed sources, Hengrui Pharmaceutical may be officially listed and traded on the Hong Kong Stock Exchange as early as May. Commentary: If Hengrui Pharmaceutical successfully goes public on the Hong Kong stock market this time, it will be its first equity financing after its A-share IPO and a key milestone in its internationalization strategy. From the current development trend of the pharmaceutical industry, overseas markets have ...
- Source: drugdu
- 39
- May 7, 2025
21 Health News Daily | The actual controller and chairman of Yong’an Pharmaceutical have been detained; Ha Sanlian and related personnel received a warning letter from Heilongjiang Securities Regulatory Bureau

Large expansion of grassroots drug catalog On April 30th, the National Health Commission issued the “Guiding Opinions on Optimizing the Layout and Construction of Grassroots Medical and Health Institutions”, once again clarifying the need to expand the types of drugs used for common and chronic diseases at the grassroots level, and promote the unification of drug catalogs for county-level medical communities. The Opinion guides various regions to comprehensively coordinate the development of urban-rural integration, changes in population structure, and public health needs, and to improve the layout and construction of grassroots medical and health institutions according to local conditions. This is in line with the State Council executive meeting’s proposal to “improve the construction layout according to local conditions”. The core goal of the policy is to optimize resource allocation and improve service capabilities, promote the implementation of tiered diagnosis and treatment, and achieve a medical pattern of “minor ...
- Source: drugdu
- 40
- May 7, 2025
The Neuralink brain computer interface device has obtained FDA’s “Breakthrough Device” certification; Hengrui Pharmaceutical Passes Hong Kong Stock Exchange Listing Hearing | Pharmaceutical Early Participation

NO.1 Hengrui Pharmaceutical has passed the listing hearing on the Hong Kong Stock Exchange and may be listed as early as May On May 5th, the Hong Kong Stock Exchange website posted the PHIP version of Hengrui Pharmaceutical’s prospectus, which the market interpreted as indicating that Hengrui Pharmaceutical has officially passed the hearing of the Hong Kong Stock Exchange. Hengrui Pharmaceutical told the Daily Economic News reporter that this move marks a crucial progress for the company’s listing in Hong Kong. According to informed sources, Hengrui Pharmaceutical may be officially listed and traded on the Hong Kong Stock Exchange as early as May. Commentary: If Hengrui Pharmaceutical successfully goes public on the Hong Kong stock market this time, it will be its first equity financing after its A-share IPO and a key milestone in its internationalization strategy. From the current development trend of the pharmaceutical industry, overseas markets have ...
- Source: drugdu
- 40
- May 7, 2025
21 Health News Daily | The actual controller and chairman of Yong’an Pharmaceutical have been detained; Ha Sanlian and related personnel received a warning letter from Heilongjiang Securities Regulatory Bureau

On April 30th, the National Health Commission issued the “Guiding Opinions on Optimizing the Layout and Construction of Grassroots Medical and Health Institutions”, once again clarifying the need to expand the types of drugs used for common and chronic diseases at the grassroots level, and promote the unification of drug catalogs for county-level medical communities. The Opinion guides various regions to comprehensively coordinate the development of urban-rural integration, changes in population structure, and public health needs, and to improve the layout and construction of grassroots medical and health institutions according to local conditions. This is in line with the State Council executive meeting’s proposal to “improve the construction layout according to local conditions”. The core goal of the policy is to optimize resource allocation and improve service capabilities, promote the implementation of tiered diagnosis and treatment, and achieve a medical pattern of “minor illnesses not leaving the village and ...
- Source: drugdu
- 38
- May 7, 2025

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.